Curis LifesciencesNSE:CURIS 19 Interest Coverage is 9.29 as of Mar. 2026, which is 4% above its 10-year median of 8.92. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 685 Drug Manufacturers companies, Curis Lifesciences ranks worse than 56.2% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Curis Lifesciences's
Operating Income
for the
six
months ended in Mar. 2026 was ₹105.7 Mil. Curis Lifesciences's Interest Expense for the
six
months ended in Mar. 2026 was ₹-11.4 Mil.
Curis Lifesciences's interest coverage for the quarter that ended in Mar. 2026 was 9.29.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Curis Lifesciences's Interest Coverage or its related term are showing as below:
NSE:CURIS'
s Interest Coverage Range Over the Past 10 Years
Min: 1.95 Med: 8.92 Max: 9.72
Current: 9.29
NSE:CURIS's Interest Coverage is ranked worse than 56.2% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs NSE:CURIS: 9.29
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Curis Lifesciences Interest Coverage Related Terms
Curis Lifesciences Interest Coverage Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Curis Lifesciences Interest Coverage Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Interest Coverage
1.95
9.72
8.54
9.29
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
Interest Coverage
1.95
9.72
8.54
9.29
NSE:CURIS vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a Interest Coverage of 9.29 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Curis Lifesciences and its competitors. This is near median its historical median of 8.92. Over the past decade, Curis Lifesciences' Interest Coverage has ranged from 1.95 to 9.72. According to the industry distribution chart, Curis Lifesciences ranks #385 out of 685 companies in the Drug Manufacturers industry, placing it in the top 56.2%.
Is Curis Lifesciences' Interest Coverage too high?
Curis Lifesciences' current Interest Coverage of 9.29 is near median its 10-year median of 8.92. Over the past 10 years, this metric has ranged from a low of 1.95 to a high of 9.72. The Drug Manufacturers industry median Interest Coverage is 12.75. Curis Lifesciences' value of 9.29 is 27.1% below this industry median. Based on the distribution chart, Curis Lifesciences ranks #385 out of 685 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #385 out of 685 companies for Interest Coverage. This places Curis Lifesciences in the lower half of its industry. The industry median Interest Coverage is 12.75. Curis Lifesciences' value of 9.29 is 27.1% below this benchmark. Historically, Curis Lifesciences' own Interest Coverage has ranged from 1.95 to 9.72 over the past decade. While the company's 10-year median is 8.92 vs. the industry median of 12.75, Curis Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current Interest Coverage of 9.29 is 27.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current Interest Coverage is 9.29, which is near median its own 10-year median of 8.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Interest Coverage of 9.29. The current Interest Coverage is 9.29, which is near median its 10-year median of 8.92 and 27.1% below the Drug Manufacturers industry median of 12.75. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Interest Coverage is 9.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 